【レポートの概要（一部）】
1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy
3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025
4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC
5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market
6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025
7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future
8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：非小細胞肺がん（NSCLC）治療薬の世界市場：市場、企業、研究開発展望■ 英文：Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5112511
■ 調査対象地域：グローバル
- Suncor Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Suncor Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Suncor Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
- 太陽光発電とカーボンナノチューブCarbon nanotubes are allotropes of carbon with a cylindrical nanostructure. Nanotubes have been constructed with length-to-diameter ratio of up to 132,000,000:1, which is significantly larger than any other material. These cylindrical carbon molecules have novel properties that make them potentially useful in many applications in nanotechnology, electronics, optics and other fields of materials sc …
- 世界の自動車ナイトビジョンシステム(NVS)市場2015The Global Automotive Night Vision Systems (NVS) Industry Report 2015 is a professional and in-depth study on the current state of the Automotive Night Vision Systems (NVS) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Automotive Night Vision Systems (NVS) market analysis is provided for the inte …
- 進化型戦闘ヘルメット（ACH）の世界市場2016-2020About Advanced Combat Helmet An ACH is a protective combat helmet used by military, homeland security, and law enforcement agencies to enhance a soldier's ballistic and impact protection. The design of an ACH has been derived from modular integrated communications helmets (MICH). An ACH can also be used as a platform to mount electronics such as communication and night vision devices. Although the …
- 世界の超伝導体市場2015The Global Superconductor Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Superconductor industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Superconductor market analysis is provided for the international markets including development trends, compe …
- 可食包装の世界市場2018-2022About Edible Packaging Edible packaging is used for coating or wrapping various food and pharmaceutical products to extend their shelf life. This type of packaging can be consumed along with the food. Technavio’s analysts forecast the global edible packaging market to grow at a CAGR of 6.26% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth p …
- ワークフロー管理システムの世界市場予測（～2021）：構成要素別（ソフトウェア、サービス）、ソフトウェア別、サービス別、導入種類別、産業別、地域別The workflow management system market is expected to grow from USD 3.51 Billion in 2016 to USD 9.87 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 23.0% during the forecast period. The increased focus on streamlining business processes, achieving cost efficiency through workflow management, and increased access to information is driving the workflow management system market across all …
- SwitzerlandのCalcium Carbonate市場：貿易（輸入、輸出）動向This market research report examines the foreign trade of Switzerland and its perspectives on the global market for Calcium carbonate. The report will be of considerable interest primarily to relevant strategic planners, senior company officials and importers/exporters, since it features invaluable information on Calcium carbonate export/import operations in Switzerland. The 2002-2012 period is co …
- ポンペ病(Pompe Disease)：世界の治験レビュー（2015年上半期版）Pompe Disease Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Pompe Disease Global Clinical Trials Review, H1, 2015" provides an overview of Pompe Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Pompe Disease. Report includes an overview of trial numbers and their average enrollment in top countries conduc …
- LNG（液化天然ガス）の世界市場：LNG生産能力、投資動向Global LNG Industry Outlook to 2019 - Capacity and Capital Expenditure Forecasts With Details of All Operating and Planned Terminals Summary "Global LNG Industry Outlook to 2019 - Capacity and Capital Expenditure Forecasts With Details of All Operating and Planned Terminals" is a comprehensive report on the global LNG industry. The report provides asset details of all active and planned LNG liquef …
- サーバーレスアーキテクチャの世界市場：展開モデル別（パブリッククラウド、プライベートクラウド）、用途別（リアルタイムファイル/ストリーム処理、Webアプリ開発、IoTバックエンド、およびその他）、組織規模別（大企業、中小企業）、業種別（金融、IT＆テレコム、ヘルスケア、製造、メディア＆エンターテイメント、公共部門、小売＆Eコマース、その他）Serverless architecture is an event-driven cloud computing model in which computing resources are provided as scalable cloud services. A fixed and recurring cost was charged for the server’s computing resources in traditional computing regardless of the amount of computing work performed by the server. However, serverless computing deployment has overcome this shortcoming, as it allows customers t …
- アンチドローンの世界市場予測（～2024年）“The anti-drone market is projected to grow at a CAGR of 28.8% from 2018 to 2024”The anti-drone market is expected to grow from USD 499 million in 2018 to USD 2,276 million by 2024, at a CAGR of 28.8%. Major factors driving the growth of this market are rising incidences of security breaches by unidentified drones and increasing terrorism and illicit activities across the world. Major restraints f …
- 世界のレザーラゲージ市場：製品別、地域別Global Leather Luggage Market: About this market Technavio’s leather luggage market analysis considers sales from travel bags, casual bags, and business bag products. Our study also finds the sales of leather luggage in APAC, Europe, MEA, North America, and South America. In 2019, the travel bags segment had a significant market share, and this trend is expected to continue over the forecast perio …
- 鉄道車両の世界市場：高速輸送車両、貨車、機関車About the global rolling stock market Rolling stock refers to wheeled railway vehicles that move on tracks, including locomotives, passenger rail vehicles, and freight wagons. These vehicles can be self-propelled or propelled. Rolling stock products are capital-intensive and require huge investment and time to manufacture. An increase in investment in rail infrastructure projects by developing cou …
- ファクタリングの世界市場2018-2022About Factoring Factoring is a service of financial nature involving the conversion of credit bill into cash. It is a process or mechanism by which a company generates finance against its receivables. Factoring is asset-based financing in which the factor gives credit by looking at the creditworthiness of the borrower. Technavio’s analysts forecast the global factoring market to grow at a CAGR of …
